Rociletinib For EGFR Lung Cancer: Phase I/II Trial Results
Thursday, April 30, 2015 - 11:20
in Health & Medicine
The investigational anti-cancer agent rociletinib (CO-1686) has received the new FDA 'Breakthrough Status' designation, developed to accelerate the approval process for very promising new medical treatments. For a new study, patients were initially given free base and later hydrogen bromide salt formulations of the drug rociletinib in ongoing 21-day cycles. The hydrogen bromide salt produced better absorption and higher drug exposure in patients and was adopted as the sole form moving forward. The New England Journal of Medicine reports results of a phase I/II study of rociletinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had progressed after previous treatment with EGFR inhibitors. read more